Exhibit
10.13  TECHNOLOGY ASSIGNMENT  THIS TECHNOLOGY ASSIGNMENT
(the Agreement) is effective only as of the Effective Time (as defined
herein) and is made by and between AnorMED Corporation (as successor in
interest to AnorMED, Inc.), a company incorporated in Canada (together
with its Affiliates, AnorMED) and Callisto Pharmaceuticals, Inc., a company
organized under the laws of Delaware (together with its Affiliates, Callisto).  Each of AnorMED and Callisto are a Party
and, together the Parties.  RECITALS  A.Johnson
Matthey Public Limited Company, an English corporation (JM), and
SmithKline Beecham Corporation, a Pennsylvania corporation (SKB),
entered into a Cooperative Research and Assignment Agreement, dated as of January 11,
1990 (the Cooperative
Agreement) for a joint research program regarding the synthesis of
certain non-metal compounds.  B.JM
and AnorMED entered into an Asset Transfer Agreement, dated as of June 28,
1996, whereby JM assigned to AnorMED all of its right, title, and interest in
the Cooperative Agreement, including valuable patent rights, technical data and
information relating to the compound Atiprimod (a/k/a Azaspiranes).  C.By
letter dated November 4, 1996, SKB terminated the Cooperative Agreement
and assigned to AnorMED all of its right, title, and interest in the
Cooperative Agreement, including valuable patent rights, technical data and
information relating to the compound Atiprimod (a/k/a Azaspiranes).  D.Pursuant
to a license agreement by and between AnorMED and Synergy Pharmaceuticals, Inc.
(Synergy)
dated as of August 28, 2002, as amended by Amendment No. 1 to License
Agreement dated as of May 23, 2003 and Amendment No. 2 to License
Agreement dated as of July 8, 2004 (the Original License), AnorMED licensed to
Synergy certain patent rights related to Atiprimod (a/k/a Azaspiranes) and one
patent application (the Jointly owned patent application).  E.Synergy
is now a wholly-owned subsidiary of Callisto.  F.AnorMED
is now a wholly-owned subsidiary of Genzyme Corporation.  G.As
of December 31, 2007, Callisto and AnorMED entered into an Amended and
Restated License Agreement (the Amended License) superceding and replacing in
its entirety the Original License.


H.The
Parties wish to terminate the Amended License and to transfer and assign to
Callisto all right, title and interest in the patent rights, technical data and
information relating to the compound Atiprimod (a/k/a Azaspiranes), on the
terms and conditions set forth herein.  AGREEMENT  NOW, THEREFORE, the parties agree as follows:  1.Definitions.  As used herein:  Affiliate shall mean any company or
other business entity controlled by, controlling or under common control with a
party, control being presumed if there is direct or indirect ownership of at
least thirty-three and one-third percent (33 1/3%) (or, if less, the maximum
permitted by applicable law) of the voting stock, equity or income interest.  Effective Time shall mean the time at which Genzyme receives the full
amount of the Payment in the account designated in Section 4 hereof.  Patent
Rights shall mean AnorMEDs interest in all the patents and patent
applications which disclose and claim Atiprimod, or an analog or derivative
thereof, or methods of use or manufacture of any of the foregoing, together
with all divisional, extensions, reissues, substitutions, renewals,
continuations and foreign counterparts thereof (including European
Supplementary Protection Certificates) and patents issuing thereon.  Exhibit A attached hereto is presumed by
the Parties to be a complete and accurate list of the Patent Rights; provided
that AnorMED may, within three (3) business days of the Effective Time,
notify Callisto that a patent or patent application listed on Exhibit A is
incorrectly included in the Patent Rights, and a patent or patent application
will not be deemed excluded from the Patent Rights if it is inadvertently
omitted from Exhibit A.  Product shall mean any product comprising or incorporating Atiprimod
(a/k/a Azaspiranes) and any analogs or derivatives described in the Patent
Rights ad used for the diagnosis, treatment or prevention of disease in humans  Technical Information shall mean all trade secrets, technical reports
and data concerning Atiprimod (a/k/a Azaspiranes) and any analogs or
derivatives described in the Patent Rights, or any pharmaceutical composition
based on the foregoing, that are necessary to develop, manufacture, have
manufactured, use or commercialize a Product, including, but not limited to,
preclinical data, toxicological studies, methods of synthesis, assay
information and clinical trial data.  Technology shall mean Patent Rights and Technical Information.  2.Assignment.  (a)Assignment.  At the Effective Time, and in return for six
hundred fifty thousand dollars ($650,000.00) (the Payment) and other consideration the
receipt and sufficiency of


which is hereby acknowledged,
AnorMED does hereby transfer, assign, set over, and convey to Callisto, and
Callistos successors and assigns, all of AnorMEDs right, title, and interest
in and to (in the United States and all foreign countries) the Technology free
and clear of all liens, mortgages, pledges, security interests, prior
assignments and encumbrances of any kind whatsoever, including without limitation
the rights, if any, to sue or bring other actions for past, present or future
infringement thereof.  AnorMED
acknowledges and agrees that the Technology and all proprietary rights to the
Technology are the sole property of Callisto. 
At Callistos request, AnorMED shall execute and deliver to Callisto one
or more separate assignments evidencing the foregoing assignment, in form and
substance reasonably satisfactory to Callisto, for filing with the United
States Patent and Trademark Office and other patent authorities throughout the
world, and perform such other acts as may be reasonably necessary to give
effect to the foregoing assignment.  (b)Files and Records.  To the extent AnorMED, or its predecessor
AnorMED, Inc., has not already done so, upon written request by Callisto,
AnorMED shall use reasonably diligent efforts to search for (and provide to
Callisto if found) any existing files and records pertaining to the Technology,
including without limitation all office actions, drafts, receipts, drawings,
correspondence, disclosures, copies, diagnostic reports, prior art and
analyses.  (c)Patent Maintenance and Enforcement
Responsibilities.Following the Effective Date, Callisto shall assume and be responsible
for maintaining and enforcing the Patent Rights, including, without limitation,
the right to sue and taking responsibility for any action or proceeding
involving the Patent Rights.  All costs
and expenses relating to the maintenance and enforcement of the Patent Rights incurred
on and after the Effective Date shall be borne solely by Callisto.  Notwithstanding the foregoing, Callisto may
elect not to maintain and enforce the Patent Rights at any time after the
Effective Date.  (d)Assignment
Recordation.  The responsibility and cost of recording the
assignment of Patent Rights shall be borne solely by Callisto.  3.Trademarks and Corporate
Name.
 All trademarks (except the AnorMED
and Genzyme mark) to be utilized by Callisto with Product are and shall be
shall be owned by Callisto.  To the extent
any such trademark is owned by AnorMED, AnorMED agrees to assign and hereby
assigns its entire right, title and interest in such trademark to Callisto, and
further agrees to execute and deliver to Callisto one or more separate
assignments evidencing the foregoing assignment, in form and substance
reasonably satisfactory to Callisto and perform such other acts as may be
reasonably necessary to give effect to the foregoing assignment. Callisto will
not use or reference AnorMEDs, Genzymes or any of their Affiliates corporate
name without the prior written consent of AnorMED, which such consent may be
withheld for any reason in AnorMEDs sole discretion, unless required by law in
which case the scope and content of such use or reference will be mutually agreed
to by the parties.  4Payment.
The Payment will be made by wire transfer on or before the close of business on
December 19, 2008 to the following account:


Beneficiary:  Genzyme Corporation Account Number
: 037-8388 Swift
Code:  MELNUS3P ABA/Routing
#:  043000261 Bank
Name:  The Bank of New York Mellon  5.Warranties; Disclaimer.  (a)Representations and
Warranties of the Parties.  Each
party represents and warrants to the other party that (a) it has full
right, power, and authority to enter into this Agreement and to carry out the
provisions hereof and (b) it has all necessary corporate approvals for its
execution, delivery and performance of this Agreement.  (b)Disclaimer.  EXCEPT FOR THE WARRANTIES SET FORTH IN SECTION 5(a),
ANORMED MAKES NO OTHER REPRESENTATIONS OR WARRANTIES WITH RESPECT TO THE PATENT
RIGHTS AND EXPRESSLY DISCLAIMS ANY OTHER WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE, PATENTABILITY AND NONINFRINGEMENT OF INTELLECTUAL PROPERTY
RIGHTS OF OTHER PARTIES.  6.Confidentiality.  (a) Confidential
Information.  Except as otherwise
provided in this Article 6, during the term of this Agreement and for a
period of five (5) years thereafter, a party (the Receiving Party) shall
keep confidential and not disclose or use (except as contemplated by this
Agreement) any proprietary or confidential information received from the other
party (the Disclosing Party), including any exchanged under the Original
License and Amended License, provided that Technical Information conveyed to
Callisto pursuant to this Agreement will be deemed confidential information
owned and disclosed by Callisto irrespective of the manner of its
disclosure.  This restriction shall not
apply to any information of the Disclosing Party to the extent the Receiving
Party can demonstrate such information (a) was already known to the
Receiving Party at the time of disclosure (as may be verified by the recipients
contemporaneous written records, and excepting Technical Information conveyed
to Callisto), (b) is or becomes public knowledge through no fault of the
Receiving Party, (c) is received without an obligation of confidentiality
from a third party having the lawful right to disclose same, or (d) was
independently developed or discovered by the Receiving Party without the use of
the information disclosed by the Disclosing Party (as may be verified by the
recipients contemporaneous written records, and excepting Technical
Information).  (b) Authorized
Disclosure.  A Receiving Party may
disclose information received from the Disclosing Party to the extent such
disclosure is (i) required by law, regulation or court order or (ii) reasonably
necessary, in connection with submissions to regulatory authorities for
purposes of this Agreement, filing or prosecuting patent applications
contemplated under this Agreement, prosecuting or defending litigation,
complying with applicable governmental regulations or conducting preclinical or
clinical trials of Product; provided, however, that in the


event of any proposed
disclosure, the Receiving Party will use its reasonable efforts to secure
confidential treatment of the information to be disclosed.  (c) Injunctive
Relief.  Receiving Party agrees that
the confidential information of the Disclosing Party constitutes valuable trade
secrets. Receiving Party further agrees that breaches of its confidentiality
and non-disclosure obligations concerning the such confidential information of
the Disclosing Party will create irreparable harm for which monetary damages
would be an inadequate remedy, and that the Disclosing Party may seek and upon
proper proof obtain (from a court with proper jurisdiction) an injunction
(without the posting of a bond or other security) to prevent any actual or
threatened breach of this Agreement, as well as damages for already caused harm
in the event of breach of any obligations herein regarding confidentiality.  7.Indemnification.  Callisto or its Affiliates shall indemnify
and defend and hold AnorMED, its Affiliates and their respective officers,
directors, employees, agents, consultants and contractors and their respective
successors, heirs and assigns (the Indemnified Parties) harmless from and
against any claim, action, liability, damage, loss, cost or expense (including
reasonable attorneys fees and expenses of litigation) (Loss) arising from or
related to (a) Callistos activities, actions, or inactions under the
Original License, the Amended License, this Agreement or any subsequent
agreement between Callisto and any third party relating to the Technology, (b) any
practice of the Patent Rights, (c) the development, testing, production,
manufacture, supply, promotion, import, sale or use of any Product or
Technology (or any component thereof) including, but not limited to, any
personal injury or product liability matters, or (d) any material breach
of this Agreement by Callisto, or (e) gross negligence or willful
misconduct on the part of Callisto or any Affiliate or sublicensee or
assignee.  AnorMED shall promptly notify
Callisto of any such claim or action, allow Callisto to control the defense of
such claim or action and render all reasonable assistance to Callisto in
connection with defending such claim or action. 
Callisto shall secure and maintain insurance commensurate with its
obligations under this Section 7 and consistent with the reasonable
standards of the industry with respect to the Product.  Callisto shall provide AnorMED with evidence
of such insurance coverage within ten (10) business days after the date of
this Agreement.  8.Effectiveness
of the Agreement.  The Parties
hereby acknowledge and agree that this Agreement is of no force and effect
prior to the Effective Time.  Further,
the Parties acknowledge and agree that, if the Effective Time does not occur on
or prior to 4pm EST on December 19, 2008, this Agreement shall be null and
void and of no force and effect unless otherwise agreed to by the Parties in a
subsequent writing.  9.Miscellaneous.  (a) Entire
Agreement; Modification.  This
Agreement constitutes the entire understanding between the parties hereto with
respect to the subject matter hereof and supersedes and cancels all prior
understandings, obligations, promises and agreements, including under the Original
License and the Amended License. Consistent with the foregoing sentence,
notwithstanding anything in the Amended License to the contrary, AnorMED and
Callisto hereby acknowledge and agree that the Amended License is hereby
terminated as of the date hereof and is of no further force or effect and that
all provisions of the Amended License, including those that


expressly or implicitly survive
termination, are hereby superseded by this Agreement effective as of the date
hereof.  No modification or amendment
hereof shall be valid or binding on the parties unless made in writing and duly
executed by the parties.  (b) Counterparts.  This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.  (c)  Notices
and Communications.  Any notice or
any other communication required or permitted to be given to a party pursuant
hereto shall be sufficiently given if delivered personally or by facsimile or
express courier service (expenses prepaid) to the address set forth below:  AnorMED:
  
  AnorMED
  Corporationc/o Genzyme
  Corporation500 Kendall
  Street, Cambridge, MA 02142Attn:
  General CounselCallisto:
  
  Callisto
  Pharmaceuticals, Inc.420
  Lexington Avenue, Suite # 1609New York, NY
  10170Attn: CEO  or to such other address as the
party shall designate by written notice given to the other party.  All notices, information, reports and other
communications in connection with this Agreement shall be in English.  (d) Governing
Law.  This Agreement shall be
governed by and construed in accordance with the laws of the Commonwealth of
Massachusetts, United States (regardless of its or any other states choice of
law provisions).  (e) Jurisdiction
and Venue.  To the fullest extent
permitted by applicable law, any action or proceeding relating in any way to
this Agreement may only be brought and enforced in the state or federal courts
located in the City of Boston, State of Massachusetts, United States, to the
extent subject matter jurisdiction exists therefore, and the Parties
irrevocably submit to the jurisdiction of such courts in respect of any such
action or proceeding.  The Parties
irrevocably waive, to the fullest extent permitted by applicable law, any
objection that they may now or hereafter have to the laying of venue of any
such action or proceeding in such courts or any claim that any such action or
proceeding brought in such court has been brought in any inconvenient forum.  Any judgment may be entered in any court
having jurisdiction thereof.  (signature page to follow)


IN WITNESS WHEREOF, the parties have caused this Agreement to be duly
executed on December 19, 2008.   ANORMED INC.By:
  /s/ Stephen MahoneyName:
  Stephen MahoneyIts:
  Assistant SecretaryCALLISTO PHARMACEUTICALS INC.By:
  /s/ Gary S. JacobName:
  Gary S. JacobIts:
  CEO


EXHIBIT A  PATENT RIGHTS  1.
  
  Title:
  
  Immunomodulatory AzaspiranesPriority Application:   USSN
  712,325      7 June 1991  Reference No.
  
  Territory
  
  Application No.
  
  Filing Date
  
  Issue Date
  
  Patent No. or
  Publication No.20015.00
  Abandoned
  
  US
  
  07/712,325
  
  7-Jun-9120015.01
  Abandoned
  
  US
  
  07/981,147
  
  24-Nov-9220015.20
  
  US
  
  08/277,456
  
  19-Jul-94
  
  7-Jan-97
  
  US 5,591,74820015.40
  
  PCT
  
  PCT/US92/04834
  
  5-Jun-92
  
  
  
  WO 92/2229420015.41
  
  EPO
  
  92914312.1
  
  5-Jun-9220015.42
  
  Ireland
  
  921,827
  
  1-Jul-9220015.43
  
  Japan
  
  500972/1993
  
  5-Jun-92
  
  2-Feb-01
  
  315527720015.44
  
  S. Korea
  
  93-703765
  
  5-Jun-92
  
  13-Jan-00
  
  25157020015.45
  Abandoned
  
  Mexico
  
  922713
  
  5-Jun-9220015.46
  Abandoned
  
  New Zealand
  
  243,029
  
  5-Jun-92
  
  29-Nov-94
  
  24302920015.47
  
  Portugal
  
  100,566
  
  4-Jun-9220015.48
  Abandoned
  
  S. Africa
  
  92/4107
  
  5-Jun-92
  
  28-Apr-93  2.
  
  Title:
  
  Cytokine InhibitorsPriority Application:   USSN 657,578      19
  February 1991  Reference No.
  
  Territory
  
  Application No.
  
  Filing
  Date
  
  Issue
  Date
  
  Patent No. or
  Publication No.20019.00
  Abandoned
  
  US
  
  07/657,578
  
  19-Feb-9120019.01 Con
  Abandoned
  
  US
  
  07/887,628
  
  22-May-9220019.02 Con 01
  
  US
  
  08/138,178
  
  15-Oct-93
  
  11-Feb-97
  
  US 5,602,16620019.03 Con 02
  
  US
  
  08/779,418
  
  7-Jan-97
  
  4-May-99
  
  US 5,900,43020019.20 CIP 02
  Abandoned
  
  US
  
  08/469,415
  
  6-Jun-9520019.40
  
  PCT
  
  PCT/US92/01283
  
  18-Feb-92
  
  
  
  WO 02/1446220019.41
  
  Australia
  
  1463392
  
  18-Feb-92
  
  11-Jul-95
  
  65774520019.42
  
  Canada
  
  2,104,214
  
  18-Feb-9220019.43
  
  European Patent Office
  
  929073625
  
  18-Feb-92
  
  17-Nov-99
  
  572537B120019.44
  
  Ireland
  
  920508
  
  18-Feb-9220019.45
  
  Japan
  
  04-507323/1992
  
  18-Feb-92
  
  23-Feb-01
  
  316207120019.46
  Abandoned
  
  S Korea
  
  93-702468
  
  18-Feb-9220019.47
  
  S Africa
  
  92/1120
  
  17-Feb-92
  
  27-Jan-93
  
  199201120


20019.48
  
  Austria
  
  92907362.5
  
  18-Feb-92
  
  17-Nov-99
  
  57253720019.49
  
  Belgium
  
  92907362.5
  
  18-Feb-92
  
  17-Nov-99
  
  57253720019.50
  
  Switzerland/
  Liechtenstein
  
  92907362.5
  
  18-Feb-92
  
  17-Nov-99
  
  57253720019.51
  
  Denmark
  
  92907362.5
  
  18-Feb-92
  
  17-Nov-99
  
  57253720019.52
  
  Spain
  
  92907362.5
  
  18-Feb-92
  
  17-Nov-99
  
  57253720019.53
  
  France
  
  92907362.5
  
  18-Feb-92
  
  17-Nov-99
  
  57253720019.54
  
  Great Britain
  
  92907362.5
  
  18-Feb-92
  
  17-Nov-99
  
  57253720019.55
  
  Greece
  
  92907362.5
  
  18-Feb-92
  
  17-Nov-99
  
  200040031120019.56
  
  Italy
  
  92907362.5
  
  18-Feb-92
  
  17-Nov-99
  
  57253720019.57
  
  Luxembourg
  
  92907362.5
  
  18-Feb-92
  
  17-Nov-99
  
  57253720019.58
  
  Monaco
  
  92907362.5
  
  18-Feb-92
  
  17-Nov-99
  
  57253720019.59
  
  Netherlands
  
  92907362.5
  
  18-Feb-92
  
  17-Nov-99
  
  57253720019.60
  
  Sweden
  
  92907362.5
  
  18-Feb-92
  
  17-Nov-99
  
  57253720019.61
  
  Germany
  
  92907362.5
  
  18-Feb-92
  
  17-Nov-99
  
  P6923031420019.62
  
  Hong Kong
  
  981133586.6


3.
  
  Title:
  
  2-[2-(Dimethylamino)ethyl]-8,8-dipropyl-2-azaspiro[4,5]decane
  dimaleatePriority Application:
  U.S. Provisional 60/016/066
  23 April 1996U.S. Provisional 60/001,134
  13 July 1995  Reference
  
  Territory
  
  Application No.
  
  Filing Date
  
  Issue Date
  
  Patent No.20021.00 (US)
  
  
  
  08/981,929
  
  11-Jul-96
  
  14-Sep-99
  
  US 5,952,365  4.
  
  Title:
  
  N,N-dimethyl-B,B-dipropyl-2-azasprio
  [4,5]decane-2-propanamine dimalcarePriority Application
  U.S. provisional 60/001,138
  13 July 1995Priority Application
  U.S. provisional 60/015,996
  23 April 1996  Reference
  
  Territory
  
  Application No.
  
  Filing Date
  
  Issue Date
  
  Patent No. or
  Publication
  No.20024.00
  
  US
  
  08/981,928
  
  12-Jul-96
  
  17-Aug-99
  
  US 5,939,45020024.40
  
  PCT
  
  PCT/US96/11590
  
  12-Jul-96
  
  
  
  WO 97/0282020024.41
  Abandoned
  
  S Africa
  
  96/5883
  
  11-Jul-96
  
  28-May-97
  
  96/588320024.42
  Abandoned
  
  EPO
  
  969260769
  
  12-Jul-96
  
  
  
  83767820024.43
  
  Japan
  
  09-505996
  
  12-Jul-96
  
  1 June 01
  
  3195364


5.
  
  Title:
  
  N,N-diethyl-8,8-dipropyl-2-azaspiro [4,5] decane-2-propanaminePriority Application:
  U.S. provisional 60/001,139
  13 July 1995U.S. provisional 60/016,065
  23 April 1996  Reference No.
  
  Territory
  
  Application
  No.
  
  Filing Date
  
  Issue Date
  
  Patent No. or
  Publication No.20029.00
  
  US
  
  08/679,480
  
  12-Jul-96
  
  28-Apr-98
  
  US 5,744,49520029.40
  Abandoned
  
  Algeria
  
  11296
  
  9-Jul-9620029.41
  
  Argentina
  
  960103537
  
  11-Jul-9620029.42
  
  Australia
  
  5945596
  
  11-Jul-96
  
  8-Jun-00
  
  71625620029.43
  Abandoned
  
  Barbados
  
  81402
  
  12-Jul-9620029.44
  
  Brazil
  
  96019093
  
  3-Jul-9620029.45
  
  Bulgaria
  
  100710
  
  8-Jul-96
  
  25-Feb-99
  
  6235920029.46
  
  Canada
  
  2,181,006
  
  11-Jul-9620029.47
  
  Chile
  
  123696
  
  12-Jul-96
  
  14-Aug-00
  
  40.65720029.48
  
  China
  
  961108207
  
  12-Jul-96
  
  1-Mar-01
  
  96110820.720029.49
  Abandoned
  
  Colombia
  
  96036764
  
  12-Jul-9620029.50
  
  Czech Rep.
  
  PV 203696
  
  9-Jul-9620029.51
  Abandoned
  
  Ecuador
  
  SP 961818
  
  11-Jul-96
  
  21-May-98
  
  P1-98136820029.52
  Abandoned
  
  Egypt
  
  66096
  
  11-Jul-9620029.53
  
  Eurasia
  
  199600048
  
  12-Jul-96
  
  3-Dec-97
  
  0 0003720029.54
  
  European Patent Office
  
  962019436
  
  11-Jul-96
  
  18-Mar-98
  
  0 75351220029.55
  
  Hungary
  
  P 9601918
  
  12-Jul-9620029.56
  
  India
  
  1557/DEL/96
  
  12-Jul-9620029.57
  
  Indonesia
  
  P 961950
  
  8-Jul-9620029.58
  Abandoned
  
  Israel
  
  118815
  
  8-Jul-96
  
  29-Sep-0020029.59
  
  Japan
  
  1830581996
  
  12-Jul-9620029.60
  
  S Korea
  
  280161996
  
  11-Jul-9620029.61
  
  Malaysia
  
  PI 9602865
  
  11-Jul-9620029.62
  
  Mexico
  
  962767
  
  12-Jul-96
  
  29-Sep-00
  
  19884320029.63
  
  New Zealand
  
  286951
  
  8-Jul-96
  
  15-Jun-98
  
  28695120029.64
  Abandoned
  
  Nigeria
  
  15396
  
  10-Jul-96
  
  6-Dec-96
  
  1257820029.65
  
  Norway
  
  962931
  
  12-Jul-96
  
  6-Dec-99
  
  306.67220029.66
  Abandoned
  
  Pakistan
  
  450/96
  
  11-Jul-96
  
  11-Nov-98
  
  13535320029.67
  Abandoned
  
  Peru
  
  52596
  
  12-Jul-9620029.68
  
  Philippines
  
  53652
  
  8-Jul-9620029.69
  
  Poland
  
  315191
  
  10-Jul-9620029.70
  
  Romania
  
  9601426
  
  11-Jul-9620029.71
  
  Saudi Arabia
  
  96170188
  
  30-Jul-9620029.72
  Abandoned
  
  Singapore
  
  96102355
  
  8-Jul-96
  
  22-Aug-00
  
  4338320029.73
  Abandoned
  
  Slovak Rep.
  
  PV 0 88696
  
  8-Jul-96
  
  18-Jan-0120029.74
  Abandoned
  
  S Africa
  
  965883
  
  11-Jul-96
  
  26-Mar-97
  
  965883


20029.75
  Abandoned
  
  Sri Lanka
  
  1103120029.76
  
  Taiwan
  
  85108324
  
  10-Jul-96
  
  21-Jan-01
  
  12689620029.77
  Abandoned
  
  Tangiers
  
  1399
  
  12-Jul-9620029.78
  
  Thailand
  
  32280
  
  9-Jul-9620029.79
  
  Turkey
  
  9600579
  
  12-Jul-96
  
  22-Mar-99
  
  TR 1996 00579 B20029.80
  Abandoned
  
  United Arab Emirates
  
  10796
  
  13-Jul-9620029.81
  Abandoned
  
  Ukraine
  
  96072764
  
  9-Jul-9620029.82
  Abandoned
  
  Uruguay
  
  24283
  
  15-Jul-9620029.83
  
  Venezuela
  
  126096
  
  12-Jul-9620029.84
  Abandoned
  
  Vietnam
  
  SC 2696
  
  12-Jul-96
  
  29-Sep-00
  
  150020029.85
  
  Austria
  
  962019436
  
  11-Jul-96
  
  18-Mar-98
  
  0 75351220029.86
  
  Belgium
  
  962019436
  
  11-Jul-96
  
  18-Mar-98
  
  0 75351220029.87
  
  Denmark
  
  962019436
  
  11-Jul-96
  
  18-Mar-98
  
  0 75351220029.88
  
  Finland
  
  962019436
  
  11-Jul-96
  
  18-Mar-98
  
  0 75351220029.89
  
  France
  
  962019436
  
  11-Jul-96
  
  18-Mar-98
  
  0 75351220029.90
  
  Germany
  
  962019436
  
  11-Jul-96
  
  18-Mar-98
  
  0 75351220029.91
  
  Greece
  
  962019436
  
  11-Jul-96
  
  18-Mar-98
  
  302699820029.92
  
  Netherlands
  
  962019436
  
  11-Jul-96
  
  18-Mar-98
  
  0 75351220029.93
  
  Ireland
  
  962019436
  
  11-Jul-96
  
  18-Mar-98
  
  0 75351220029.94
  
  Italy
  
  962019436
  
  11-Jul-96
  
  18-Mar-98
  
  0 75351220029.95
  
  Luxembourg
  
  962019436
  
  11-Jul-96
  
  18-Mar-98
  
  0 75351220029.96
  Abandoned
  
  Morocco
  
  24311
  
  12-Jul-9620029.97
  
  Portugal
  
  962019436
  
  11-Jul-96
  
  18-Mar-98
  
  0 75351220029.98
  
  Spain
  
  962019436
  
  11-Jul-96
  
  18-Mar-98
  
  0 75351220029.99
  
  Sweden
  
  962019436
  
  11-Jul-96
  
  18-Mar-98
  
  0 75351225029.40
  
  Switzerland
  
  962019436
  
  11-Jul-96
  
  18-Mar-98
  
  0 75351225029.41
  Abandoned
  
  Hong Kong
  
  981107432
  
  18-Sep-98
  
  11-Jun-99
  
  HK101005225029.42
  
  Great Britain
  
  962019436
  
  11-Jul-96
  
  18-Mar-98
  
  753512


6.
  
  Title       Immunomodulatory
  azaspiranesPriority Application:       USSN
  101,704       28 September 1987  Reference
  No.
  
  Territory
  
  Application No.
  
  Filing Date
  
  Issue Date
  
  Patent No. or
  Publication
  No.20031.00
  Abandoned
  
  US
  
  07/101,704
  
  28-Sep-8720031.20 CIP
  20031.00
  
  US
  
  07/244,229
  
  13-Sep-88
  
  16-Oct-90
  
  US 4,963,55720031.40
  
  PCT
  
  PCT/US88/03323
  
  27-Sep-8820031.41
  Abandoned
  
  Bahamas
  
  930
  
  27-Sep-88
  
  14-Apr-89
  
  93020031.42
  
  Canada
  
  578528
  
  27-Sep-88
  
  26-Apr93
  
  131318920031.43
  
  China
  
  881090328
  
  27-Sep-88
  
  21-Jan-96
  
  88109032820031.44
  
  Cyprus
  
  883089146
  
  26-Sep-88
  
  12-Sep-96
  
  195520031.45
  
  Czech Rep
  
  PV 397091
  
  20-Dec-0120031.46
  
  European Patent Office
  
  883089146
  
  26-Sep-88
  
  30-Nov-94
  
  031032120031.47
  
  Ireland
  
  292988
  
  28-Sep-88
  
  16-Apr-96
  
  6789120031.48
  Abandoned
  
  Israel
  
  87908
  
  25-Sep-88
  
  21-Feb-93
  
  8790820031.49
  Abandoned
  
  Malaysia
  
  8801078
  
  27-Sep-88
  
  30-Jul-94
  
  10493220031.50
  
  Mexico
  
  923765
  
  29-Jun-92
  
  10-May-94
  
  17436720031.51
  
  New Zealand
  
  226354
  
  27-Sep-88
  
  13-Jun-91
  
  22635420031.52
  Abandoned
  
  Pakistan
  
  43988
  
  28-Sep-88
  
  26-Dec-90
  
  13149720031.53
  
  Portugal
  
  88603
  
  27-Sep-88
  
  25-Jun-92
  
  8860320031.54
  Abandoned
  
  Singapore
  
  96914205
  
  26-Sep-88
  
  30-Nov-94
  
  9691420520031.55
  
  Slovakia
  
  397097
  
  20-Dec-9120031.56
  Abandoned
  
  S Africa
  
  887266
  
  28-Sep-88
  
  27-Jan-93
  
  88726620031.57
  
  Taiwan
  
  77106657
  
  24-Sep-88
  
  26-Apr-91
  
  4387120031.58
  Abandoned
  
  Zimbabwe
  
  12388
  
  21-Sep-88
  
  7-Apr-89
  
  1238820031.59
  
  Australia
  
  253388
  
  27-Sep-88
  
  1-Jun-92
  
  61978020031.60
  
  Denmark
  
  77090
  
  27-Sep-88
  
  8-May-95
  
  17004220031.61
  
  Finland
  
  901530
  
  27-Sep-88
  
  10-Feb-95
  
  9300620031.62
  Abandoned
  
  Hungary
  
  588988
  
  27-Sep-88
  
  24-Sep-93
  
  20880920031.63
  
  Japan
  
  63508105
  
  27-Sep-88
  
  21-Nov-96
  
  258288820031.64
  Abandoned
  
  S Korea
  
  899-00907
  
  27-Sep-88
  
  22-Sep-98
  
  16636620031.65
  
  Norway
  
  901392
  
  27-Sep-88
  
  9-Feb-94
  
  17382420031.66
  
  Philippines
  
  37609
  
  13-Sep-88
  
  5-Nov-91
  
  2581220031.67
  Abandoned
  
  Hungary
  
  P/P00121
  
  1-Jul-95
  
  
  
  21132520031.68
  
  Austria
  
  883089146
  
  26-Sep-88
  
  30-Nov-94
  
  0 31032120031.69
  
  Belgium
  
  883089146
  
  26-Sep-88
  
  30-Nov-94
  
  0 31032120031.70
  
  France
  
  883089146
  
  26-Sep-88
  
  30-Nov-94
  
  0 31032120031.71
  
  Germany
  
  883089146
  
  26-Sep-88
  
  30-Nov-94
  
  0 31032120031.72
  
  Great Britain
  
  883089146
  
  26-Sep-88
  
  30-Nov-94
  
  0 31032120031.73
  
  Greece
  
  883089146
  
  26-Sep-88
  
  30-Nov-94
  
  0 310321


20031.74
  
  Italy
  
  883089146
  
  26-Sep-88
  
  30-Nov-94
  
  0 31032120031.75
  
  Luxembourg
  
  883089146
  
  26-Sep-88
  
  30-Nov-94
  
  0 31032120031.76
  
  Netherlands
  
  883089146
  
  26-Sep-88
  
  30-Nov-94
  
  0 31032120031.77
  
  Spain
  
  883089146
  
  26-Sep-88
  
  30-Nov-94
  
  0 31032120031.78
  
  Sweden
  
  883089146
  
  26-Sep-88
  
  30-Nov-94
  
  0 31032120031.79
  Abandoned
  
  Hong Kong
  
  98105430
  
  
  
  
  
  HK 1006274


7.Psoriasis treatment
using Azaspiranes and a method of immunosuppression, using Azaspiranes in
combination with cyclosporine)  Patent No. US 5,981,538 Patent No. US 6,051,59